*
*
* Dr
* Dr
The Board has determined that given the refreshment of the Board following the Demerger and the Company's renewed focus the whole Board will engage with the workforce to gather employees' perspectives rather than designating a specific Non-Executive Director for this purpose. A programme of events is in place to facilitate engagement with employees to gather and understand directly their views.
As previously announced:
*
*
These changes continue the transition of the Board as an independent biopharma company post separation. GSK expects to announce further Non-Executive Director appointments shortly.
Board and Committee Membership with effect from 18 July 2022:Board Membership
Sir
Dr
Dr
Dr
Dr
Dr
Dr
Non-Executive Chair
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer
Senior Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
*
Dr
Dr
Remuneration Committee
Dr
Sir
Dr
Corporate Responsibility Committee
Dr
Dr
Dr
Science Committee
Dr
Dr
Dr
Dr
Chairs' Committee
Sir
Senior Independent Non-Executive Director
Chairs of the Board's Committees
* Audit committee financial expert
** Scientific and Medical Expert
Company Secretary
Notes
A. The following information is available for reference on www.GSK.com:
1
Biographies of each Board member
Board of directors and leadership team | GSK
2
Terms of reference of each Board Committee
Committees | GSK
3
Current Non-Executive Director Fees
Non-Executive Director Fees
B.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and any impacts of the COVID-19 pandemic.
.
(C) 2022 M2 COMMUNICATIONS, source